Oxaliplatin Kabi

Oxaliplatin, the active ingredient in Oxaliplatin Kabi, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous infusion use. It is employed in the treatment of colorectal cancer, typically in combination regimens for adult patients. GNH USA supplies Oxaliplatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Kabi is used in colorectal cancer treatment protocols that target the adenocarcinoma pathway.

- Metastatic colorectal cancer: Enhances tumor response when combined with fluoropyrimidine‑based regimens. - Adjuvant colorectal cancer: Reduces risk of disease recurrence after surgical resection. - Advanced solid tumours (off‑label): May be considered within clinical trial settings for other gastrointestinal malignancies. - Stage III colorectal cancer: Supports curative intent treatment. - Stage S  ?? ???  ---  ?? --- --- --- --- --- --- --- --- -  ??? --- 

The         … … ... ... ...